Chemo-immunotherapy before surgery for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that hasn't spread to other parts of the body.
- Your tumor has a PD-L1 level of 1% or higher (a protein that may help the immunotherapy work).
- You do not have certain gene changes (EGFR, ALK, ROS1, or RET) in your tumor.
- You are healthy enough to have surgery and chemotherapy, with good lung and organ function.
- You have not had any previous treatment for this lung cancer, including chemotherapy or radiation.
- You are 18 years or older and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This study tests a new approach: giving an immunotherapy drug (tislelizumab) plus chemotherapy before surgery or radiation for advanced lung cancer that has spread to chest lymph nodes. The goal is to shrink the cancer first, then remove or treat it, to improve chances of long-term control.
Hear when a new Stage III NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.